A

AlloVir
D

ALVR

0.55800
USD
-0.01
(-1.78%)
Market Closed
Volume
3,130
EPS
0
Div Yield
-
P/E
-1
Market Cap
64,469,395
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    AAPL
    -3.130
    (-1.37%)
    229.75 USD
    AMZN
    AMZN
    -8.930
    (-4.22%)
    197.06 USD
    GOOGL
    GOOGL
    -3.110
    (-1.77%)
    164.75 USD
    MSFT
    MSFT
    -11.75
    (-2.75%)
    417.03 USD
    NVDA
    NVDA
    -4.900
    (-3.34%)
    141.9 USD
    S
    SNAP
    -0.165
    (-1.53%)
    10.600 USD
    TSLA
    TSLA
    9.69
    (3.11%)
    352.65 USD
    Z
    ZM
    -1.500
    (-1.82%)
    81.120 USD
    More
News

Title: AlloVir

Sector: Healthcare
Industry: Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.